Search Results for keywords:"Drug Enforcement Administration"

LTS Therapy Systems, LLC is seeking to become a registered importer of certain controlled substances for research and development purposes. The Drug Enforcement Administration (DEA) is asking for public comments or objections to this application by April 7, 2025. Comments must be submitted electronically through the Federal eRulemaking Portal. The company is not permitted to import these substances for commercial sale, and any registration approval will align with legal requirements.

The Drug Enforcement Administration (DEA) has announced that Natural Fulfillment LLC has applied to become a registered manufacturer to produce controlled substances in bulk, particularly marihuana, for scientific and medical research. Interested parties, including other registered manufacturers and applicants, have until March 15, 2021, to submit their comments or raise objections to this application. If approved, Natural Fulfillment LLC will be authorized to produce bulk active pharmaceutical ingredients (APIs) for distribution to DEA-registered researchers, in compliance with all relevant laws and regulations to prevent misuse.

Kinetochem LLC has filed an application to be registered as a bulk manufacturer of certain controlled substances. The company plans to manufacture these substances, including synthetic versions of Marihuana and Tetrahydrocannabinols, for use as Active Pharmaceutical Ingredients in research and clinical trials. The public or other manufacturers may submit comments or objections electronically by February 4, 2025, through the Federal eRulemaking Portal.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause to Laura M. Bellew, a nurse practitioner from New Mexico, proposing to revoke her DEA registration because she no longer has the authority to handle controlled substances in New Mexico. This is because her nursing licenses were suspended by the New Mexico State Board of Nursing in January 2023. Bellew did not request a hearing to contest the charges, effectively admitting the DEA's allegations. As a result, the DEA decided to revoke her registration and deny any pending applications related to controlled substances in New Mexico.

The Drug Enforcement Administration (DEA) has revoked the DEA registration of Dr. Victor Augusto Silva from Tampa, Florida, due to his failure to comply with federal and state laws regarding controlled substances. The DEA found that Dr. Silva allowed an unauthorized individual to use his registration to issue prescriptions for controlled substances, which is against the law. As Dr. Silva did not adequately respond to the charges or demonstrate he can be trusted with prescribing controlled substances, the DEA determined his continued registration would not serve the public interest. As a result, his registration was revoked, and any pending applications for registration in Florida were denied.

The Drug Enforcement Administration (DEA) issued an Order to Show Cause and Immediate Suspension of Registrations to Empire Pharmacy and Skyline Pharmacy in Philadelphia, claiming their activities posed an imminent danger to public health. Between 2019 and 2023, the pharmacies failed to maintain accurate records of controlled substances, violating federal and state laws. When the pharmacies did not request a hearing to dispute these claims, the DEA moved forward with final actions to revoke their registrations. Due to their failure to comply and their inadequate responses, the DEA decided to revoke both pharmacies' DEA Certificates of Registration.

Pharmaron Manufacturing Services (US) LLC has applied to be registered as an importer of certain controlled substances. The Drug Enforcement Administration (DEA) announced this application and is inviting comments and requests for hearings from other registered bulk manufacturers and applicants until April 25, 2025. The company aims to use the imported substances for analytical purposes and production processes but is not authorized for commercial sale of finished dosage forms. The submission of comments should be done electronically through the Federal eRulemaking Portal.

Curia New York, Inc. has applied to the Drug Enforcement Administration (DEA) to become an importer of controlled substances. The company intends to use these substances in bulk manufacturing to produce other controlled substances for their clients. Public feedback on the application can be submitted electronically until January 29, 2025. The application must align with DEA regulations and does not permit importing finished or unfinished drug products for commercial sale.

Organic Standards Solutions International, LLC has applied to the Drug Enforcement Administration (DEA) to register as an importer of certain controlled substances. The company aims to import substances like Marihuana Extract, Marihuana, and a synthetic version of Tetrahydrocannabinols to create analytical reference standards for customers. The public can comment or request a hearing on this application by January 6, 2025, through the Federal eRulemaking Portal. Permits will be approved only if the business activities align with legal requirements, and the company is not authorized to import FDA-approved or non-approved finished products for sale.

The Drug Enforcement Administration (DEA) has announced that the University of Kentucky Cannabis Center has applied to become a registered bulk manufacturer of controlled substances, specifically marihuana. This application, filed on July 1, 2024, aims to allow the center to produce bulk active pharmaceutical ingredients for research purposes. Interested parties can comment on or object to this application until April 14, 2025, through the Federal eRulemaking Portal. DEA will review the application to ensure it complies with laws and regulations, focusing on preventing the potential diversion of the controlled substance.